As off-label use continues to expand, particularly among patients with obesity or insulin resistance, our findings suggest GLP-1based therapies may warrant consideration as an adjunct to insulin in carefully selected patients. Advertisement Advertisement New service for patients with diabetes will make annual screening more convenient Association revises criteria for the diagnosis and resolution of severe conditions What to consider in the management of euglycemic DKA Less than 50% of patients with diabetes get appropriate ophthalmic screening through primary care referrals Familiarity will enhance its accessibility for patients with diabetes New study counters earlier findings linking drugs with eye disease Study highlights the value of quantitative ultra-widefield angiography Longevity in healthcare, personal experiences may provide caregivers with false sense of confidence
In the SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., NEJM 2015), participants receiving Saxenda alongside lifestyle modification achieved mean weight loss of approximately 8% of initial body weight, compared with 2.6% in the placebo group
Brand-Name Options in Western States PlexusDx sources semaglutide from licensed 503A compounding pharmacies, which manufacture medications under stricter quality controls than large-scale facilities
They are stating that the medication will maintain at least 90% of its labeled potency and meet all quality specifications (sterility, pH, particulate matter) through that date, assuming proper storage
Badman, M
:quality(85):upscale()/2024/09/19/783/n/49351082/2c557c9c66ec63d36577f4.31206634_.jpg)
